Endometrial

NRG CC014 (XRT at MBMC Only)

Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

---

EAY191-N4

A Randomized Trial of Selumetinib + Olaparib or Selumetinib Alone in pts with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: ComboMATCH Treatment Trial

---

EAQ222CD ***NON-METASTATIC COHORT CLOSED TO ACCRUAL EFFECTIVE 1/13/26****

Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients

---

NRG-GY026 **Registration to Stage I and Stage II is Temporarily Closed to Accrual as of 04/29/2024** (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)

A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-Iv Endometrial Serous Carcinoma Or Carcinosarcoma

---

URCC 19185

Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

---

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---